Menu
GWAS Study

Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors.

Melin BS, Barnholtz-Sloan JS, Wrensch MR et al.

28346443 PubMed ID
GWAS Study Type
30659 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

MB
Melin BS
BJ
Barnholtz-Sloan JS
WM
Wrensch MR
JC
Johansen C
ID
Il'yasova D
KB
Kinnersley B
OQ
Ostrom QT
LK
Labreche K
CY
Chen Y
AG
Armstrong G
LY
Liu Y
EJ
Eckel-Passow JE
DP
Decker PA
LM
Labussière M
IA
Idbaih A
HK
Hoang-Xuan K
DS
Di Stefano AL
MK
Mokhtari K
DJ
Delattre JY
BP
Broderick P
GP
Galan P
GK
Gousias K
SJ
Schramm J
SM
Schoemaker MJ
FS
Fleming SJ
HS
Herms S
HS
Heilmann S
NM
Nöthen MM
WH
Wichmann HE
SS
Schreiber S
SA
Swerdlow A
LM
Lathrop M
SM
Simon M
SM
Sanson M
AU
Andersson U
RP
Rajaraman P
CS
Chanock S
LM
Linet M
WZ
Wang Z
YM
Yeager M
WJ
Wiencke JK
HH
Hansen H
ML
McCoy L
RT
Rice T
KM
Kosel ML
SH
Sicotte H
AC
Amos CI
BJ
Bernstein JL
DF
Davis F
LD
Lachance D
LC
Lau C
MR
Merrell RT
SJ
Shildkraut J
AF
Ali-Osman F
SS
Sadetzki S
SM
Scheurer M
SS
Shete S
LR
Lai RK
CE
Claus EB
OS
Olson SH
JR
Jenkins RB
HR
Houlston RS
BM
Bondy ML
Chapter II

Abstract

Summary of the research findings

Genome-wide association studies (GWAS) have transformed our understanding of glioma susceptibility, but individual studies have had limited power to identify risk loci. We performed a meta-analysis of existing GWAS and two new GWAS, which totaled 12,496 cases and 18,190 controls. We identified five new loci for glioblastoma (GBM) at 1p31.3 (rs12752552; P = 2.04 × 10-9, odds ratio (OR) = 1.22), 11q14.1 (rs11233250; P = 9.95 × 10-10, OR = 1.24), 16p13.3 (rs2562152; P = 1.93 × 10-8, OR = 1.21), 16q12.1 (rs10852606; P = 1.29 × 10-11, OR = 1.18) and 22q13.1 (rs2235573; P = 1.76 × 10-10, OR = 1.15), as well as eight loci for non-GBM tumors at 1q32.1 (rs4252707; P = 3.34 × 10-9, OR = 1.19), 1q44 (rs12076373; P = 2.63 × 10-10, OR = 1.23), 2q33.3 (rs7572263; P = 2.18 × 10-10, OR = 1.20), 3p14.1 (rs11706832; P = 7.66 × 10-9, OR = 1.15), 10q24.33 (rs11598018; P = 3.39 × 10-8, OR = 1.14), 11q21 (rs7107785; P = 3.87 × 10-10, OR = 1.16), 14q12 (rs10131032; P = 5.07 × 10-11, OR = 1.33) and 16p13.3 (rs3751667; P = 2.61 × 10-9, OR = 1.18). These data substantiate that genetic susceptibility to GBM and non-GBM tumors are highly distinct, which likely reflects different etiology.

12,469 European ancestry cases, 18,190 European ancestry controls.

Chapter III

Study Statistics

Key metrics and study information

30659
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
U.S., Australia, France, Germany, China, Israel, Denmark, Sweden, U.K.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.